他达拉非对结缔组织病相关肺动脉高压临床疗效观察  

Clinical observation of tadalafil on pulmonary hypertension associated with connective tissue disease

作　　者：赵颖 谷新顺[2] 李薇薇[1] 汪雁博[2] 郝国贞[2] 傅向华[2] 张立新[1] 马涛[1] 田立国[1] 王丹丹 ZHAO Ying;GU Xinshun;LI Weiwei;WANG Yanbo;HAO Guozhen;FU Xianghua;ZHANG Lixin;MA Tao;TIAN Liguo;WANG Dandan(Department of Cardiology Qinhuangdao HaiGang Hospital,Qinhuangdao 066000,China)

机构地区：[1]秦皇岛市海港医院心内科,066000 [2]河北医科大学第二医院心内科

出　　处：《心肺血管病杂志》2020年第5期554-558,共5页Journal of Cardiovascular and Pulmonary Diseases

摘　　要：目的:本研究旨在探讨他达拉非(Tadalafil)对结缔组织病相关性肺动脉高压(CTD-PAH)患者肺动脉收缩压(sPAP)、右心室(RV)收缩功能及6 min步行试验(6MWD)等血流动力学参数及运动能力的影响,以评价其临床疗效。方法:本文连续入组52例诊断为CTD-PAH患者,所有患者入院后接受右心导管(RHC)检查,随机分为他达拉非组(23例)及对照组(29例),他达拉非组于诊断确立后给予他达拉非10 mg每日1次,口服,对照组给予贝前列腺素钠40μg,每日3次,口服。两组患者入院时及用药3个月后,复查超声心动图及6MWD等进行评估。主要结果是在治疗3个月后三尖瓣反流速度(TRV)、sPAP的超声心动图参数变化。结果:两组患者入院时基线TRV、sPAP、6MWD水平等,差异无统计学意义(P>0.05),用药3个月后,他达拉非组TRV、sPAP、6MWD水平等多项指标治疗后明显改善,且改善效果优于对照组(P<0.05)。结论:他达拉非用于治疗CTD-PAH患者安全有效。Objective:The purpose of this study was to investigate the influence of Tadalafil to the hemodynamic parameters and exercise ability such as systolic pulmonary artery pressure(sPAP)and Right Ventricular(RV)systolic function and walking test(6MWD)in patients with connective tissue disease related pulmonary hypertension(CTD-PAH),to appraise the clinical efficacy.Methods:This prospective study enrolled 52 consecutive patients diagnosed with CTD-PAH,all included patients underwent right heart catherization(RHC)examination after admission.The participants were randomized divided into the Tadalafil group(23 cases)and the control group(29 cases),Tadalafil group give Tadalafil 10 mg once a day,and the control group given Beraprost 40ug three times a day.Patients in both groups were evaluated by echocardiography and 6MWD at admission and 3 months after administration.The main outcome were the changes in echocardiographic parameters of tricuspid regurgitation velocity(TRV)and systolic sPAP 3 months after treatment.Results:there was no significant difference in baseline TRV,sPAP and 6MWD levels between the two groups at admission(P>0.05).After 3 months of treatment,TRV,sPAP and 6MWD levels in Tadalafil group were significantly improved after treatment,and the improvement effect was better than the control group(P<0.05).Conclusions:Tadalafil is safe and effective for CTD-PAH patients.

关 键 词：肺动脉高压 右心衰竭 结缔组织相关肺动脉高压 他达拉非 

分 类 号：R54[医药卫生—心血管疾病]